Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim and Eli Lilly and Company have entered into a global alliance to jointly develop and commercialise a portfolio of diabetes compounds currently in mid- and late-stage development.
Subscribe to our email newsletter
The compounds are Boehringer Ingelheim‘s two oral diabetes agents – linagliptin and BI10773 as well as Lilly‘s two basal insulin analogues – LY2605541 and LY2963016.
The agreement also includes an option for Boehringer Ingelheim to co-develop and co-commercialise another Lilly diabetes molecule, an anti-TGF-beta monoclonal antibody.
The partnership will combine collective scientific expertise and business capabilities of the two companies to meet patient needs arising from the growing global diabetes epidemic.
Under the terms of agreement, Eli Lilly will make an initial one-time payment to Boehringer Ingelheim of €300m, and Boehringer Ingelheim will be eligible to receive up to a total of €625m based on the success-based regulatory milestones for linagliptin and BI10773.
Lilly will be eligible to receive a total of $650m based on success-based regulatory milestones on its two basal insulin analogues.
If Boehringer Ingelheim opts to the Phase III development and potential commercialisation of the anti-TGF-beta monoclonal antibody, Lilly would be eligible to receive up to $525m in opt-in and success-based regulatory milestone payments.
The companies will share the ongoing development costs equally, and will equally share in the product’s commercialisation costs and gross margin upon successful regulatory approval of any product resulting from the alliance.